CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR T cells
Aug 20, 2020
SHANGHAI,?Aug. 20, 2020?/PRNewswire/ --?CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced that the National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application for the first-in-class drug candidate CT041, autologous chimeric antigen receptor (CAR) T cells for the treatment of claudin18.2-positive solid tumors.